A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools by Lin, H-H et al.
A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools 
Hsien-Ho Lin*1,2,3, Ivor Langley*4, Reuben Mwenda5, Basra Doulla6, Saidi Egwaga6, Kerry A. Millington4, Gillian H. Mann4, Megan Murray7, S Bertel Squire4 and Ted Cohen7,8 

*Joint first authors
1Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taiwan
2International Union Against Tuberculosis and Lung Disease
3Department of Community Health, Mennonite Christian Hospital, Taiwan
4Liverpool School of Tropical Medicine, Liverpool, UK
5Health Technical Support Services (Diagnostics), Ministry of Health, Lilongwe, Malawi
6National Tuberculosis and Leprosy Control Program, Ministry of Health and Social Welfare, Dar es Salaam, United Republic of Tanzania
7Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
8Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA

Corresponding author: Ted Cohen, Division of Global Health Equity, Brigham and Women's Hospital, Assistant Professor in Epidemiology, Harvard School of Public Health, Boston, USA
Running head (max 45 letters and spaces): Modelling new tuberculosis diagnostic tools 











Efforts to stimulate technological innovation in the diagnosis of tuberculosis have resulted in the recent introduction of several novel diagnostic tools. As these products come to market, policy makers must make difficult decisions about which of the available tools to implement. This choice should depend not only on the tools’ test characteristics (e.g. sensitivity and specificity), but also on how they will be used within the existing health care infrastructure. Accordingly, policy makers choosing between diagnostic strategies must decide: 1) What is the best combination of tools to select?; 2) Who should be tested with the new tools?; and 3) Will these tools complement or replace existing diagnostics? The best choice of diagnostic strategy will likely vary between settings with different epidemiology (e.g. levels of TB incidence, HIV co-infection, and drug-resistant TB) and structural and resource constraints (e.g. existing diagnostic pathways, human resources and laboratory capacity). 

We propose a joint modelling framework that includes a TB transmission component (a dynamic epidemiological model) and a health system component (an operational systems model) to support diagnostic strategy decisions. This modelling approach captures the complex feedback loops in this system: new diagnostic strategies alter the demands on and the performance of health systems which impact TB transmission dynamics which, in turn, result in further changes to the demands on the health system. We demonstrate the use of a simplified model to support the rational choice of diagnostic strategy based on health systems requirements, patient outcomes, and population level TB impact.
   
INTRODUCTION
Investment in and coordination of efforts to develop new diagnostic tests for TB have resulted in promising new tools (e.g. PCR-based DNA amplification tests), and modifications of existing approaches (e.g. LED microscopy, front-loading, and sputum processing with bleach or by centrifugation). ADDIN EN.CITE 1-6 Faced with this growing arsenal of diagnostic options, policy makers must make difficult choices about which new technology or combination of technologies to implement, and how to incorporate them in diagnostic algorithms. These choices are further complicated by the rapidly-changing policy environment where investments made based on current recommendations might need to be modified in response to subsequent recommendations. HYPERLINK  \l "_ENREF_7" \o "van Kampen, 2010 #104"  ADDIN EN.CITE <EndNote><Cite><Author>van Kampen</Author><Year>2010</Year><RecNum>104</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>104</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>van Kampen, S. C.</author><author>Ramsay, A. R.</author><author>Anthony, R. M.</author><author>Klatser, P. R.</author></authors></contributors><auth-address>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland. sanne.vankampen@gmail.com</auth-address><titles><title>Retooling national TB control programmes (NTPs) with new diagnostics: the NTP perspective</title><secondary-title>PLoS One</secondary-title></titles><periodical><full-title>PLoS One</full-title></periodical><pages>e11649</pages><volume>5</volume><number>7</number><edition>2010/07/28</edition><keywords><keyword>Disease Management</keyword><keyword>Humans</keyword><keyword>Tuberculosis/*diagnosis</keyword><keyword>World Health Organization</keyword></keywords><dates><year>2010</year></dates><isbn>1932-6203 (Electronic)&#xD;1932-6203 (Linking)</isbn><accession-num>20661463</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/20661463</url></related-urls></urls><custom2>2908286</custom2><electronic-resource-num>10.1371/journal.pone.0011649</electronic-resource-num><language>eng</language></record></Cite></EndNote>7 Ideally, policy makers would select the most cost-effective tools that best improve patient outcomes and, by reducing the expected duration of undetected infectious disease, limit transmission in the community. In reality, understanding the health system requirements and population-level impact of diagnostic tools is challenging because the long-term dynamics of TB epidemics make it difficult to measure the epidemiological impact of interventions and the wide array of tools (and potential combination of these tools) makes testing and comparing all options impossible. 

While most previous studies of the potential impact of new TB diagnostics have focused on the test characteristics of the tools (i.e. sensitivity and specificity) ADDIN EN.CITE 8, 9, we suggest that a more complete understanding of impact also requires consideration of how these tools will be used within diagnostic pathways. Accordingly, these decisions require the comparison of different diagnostic strategies that incorporate consideration of both the technical characteristics of the tools and how these tools will actually be implemented within a health system, and at what cost. Different diagnostic strategies may prove superior in settings with different levels of HIV-associated TB or drug-resistant TB or in areas with a different existing health care infrastructure. 

Traditionally, separate modelling approaches have been used to project the impact of new interventions on disease dynamics (i.e. dynamic epidemiological modelling) and to understand the impact of new technologies on the performance of health systems (i.e. operational modelling). While several previous studies have discussed the importance of the health system context for TB diagnostics, ADDIN EN.CITE 8, 10-13 a practical methodology for bringing this context into rational policy decision-making has not been suggested. We therefore propose a new type of linked model to assess the potential impact of new diagnostic strategies on health system costs and infrastructure, patient access and outcomes, and the TB epidemic. Since there is feedback between the dynamic epidemiological and operational aspects of the system (Figure 1), this linked modelling approach provides a natural framework for these comparisons.

Here, using a simplified example of a new diagnostic tool that requires less processing time, fewer patient visits, and has increased test sensitivity in comparison to smear microscopy, we illustrate the development and use of a linked modelling approach for assessing effects. We first introduce each modelling component separately; we then describe how they can be linked to compare different diagnostic strategies. 

DEFINING POTENTIAL IMPACT OF A NEW DIAGNOTIC TOOL
Standard approaches for the diagnosis of pulmonary TB rely on microscopic examination of sputum samples collected from TB suspects over at least two days. This approach has several clear limitations: it requires that a patient return to a health care facility more than once resulting in higher costs to patients HYPERLINK  \l "_ENREF_14" \o "Kemp, 2007 #2"  ADDIN EN.CITE <EndNote><Cite><Author>Kemp</Author><Year>2007</Year><RecNum>2</RecNum><DisplayText><style face="superscript">14</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kemp, J. R.</author><author>Mann, G.</author><author>Simwaka, B. N.</author><author>Salaniponi, F. M.</author><author>Squire, S. B.</author></authors></contributors><auth-address>Equi-TB Knowledge Programme, Malawi and Liverpool School of Tropical Medicine, UK. jkemp@africa-online.net</auth-address><titles><title>Can Malawi&apos;s poor afford free tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in Lilongwe</title><secondary-title>Bull World Health Organ</secondary-title></titles><periodical><full-title>Bull World Health Organ</full-title></periodical><pages>580-5</pages><volume>85</volume><number>8</number><edition>2007/09/05</edition><keywords><keyword>Antitubercular Agents/therapeutic use</keyword><keyword>*Cost of Illness</keyword><keyword>Cross-Sectional Studies</keyword><keyword>Female</keyword><keyword>Health Expenditures</keyword><keyword>Health Services Accessibility/*economics/organization &amp; administration</keyword><keyword>Humans</keyword><keyword>Malawi/epidemiology</keyword><keyword>Male</keyword><keyword>*Poverty</keyword><keyword>Transportation</keyword><keyword>Tuberculosis, Pulmonary/*diagnosis/drug therapy/*economics</keyword></keywords><dates><year>2007</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>0042-9686 (Print)&#xD;0042-9686 (Linking)</isbn><accession-num>17768515</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17768515</url></related-urls></urls><custom2>2636388</custom2><electronic-resource-num>S0042-96862007000800009 [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>14 and more opportunity for losses to follow up, ADDIN EN.CITE 15-17 cannot differentiate between M. tuberculosis and other non-tuberculosis mycobacteria, and does not detect drug resistance.

There are several different potential levels of effect from a new diagnostic tool that overcomes these limitations (Table 1). First, the new diagnostic may have a beneficial effect for patients who receive early diagnosis because of a test with increased sensitivity. A test not requiring multiple visits will reduce patient costs and limit losses to follow up HYPERLINK  \l "_ENREF_4" \o "Ramsay, 2009 #101"  ADDIN EN.CITE <EndNote><Cite><Author>Ramsay</Author><Year>2009</Year><RecNum>101</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>101</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">101</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ramsay, A.</author><author>Yassin, M. A.</author><author>Cambanis, A.</author><author>Hirao, S.</author><author>Almotawa, A.</author><author>Gammo, M.</author><author>Lawson, L.</author><author>Arbide, I.</author><author>Al-Aghbari, N.</author><author>Al-Sonboli, N.</author><author>Sherchand, J. B.</author><author>Gauchan, P.</author><author>Cuevas, L. E.</author></authors></contributors><auth-address>Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.</auth-address><titles><title>Front-loading sputum microscopy services: an opportunity to optimise smear-based case detection of tuberculosis in high prevalence countries</title><secondary-title>J Trop Med</secondary-title></titles><periodical><full-title>J Trop Med</full-title></periodical><pages>398767</pages><volume>2009</volume><edition>2009/01/01</edition><dates><year>2009</year></dates><isbn>1687-9694 (Electronic)&#xD;1687-9686 (Linking)</isbn><accession-num>20309419</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/20309419</url></related-urls></urls><custom2>2836912</custom2><electronic-resource-num>10.1155/2009/398767</electronic-resource-num><language>eng</language></record></Cite></EndNote>4 and individuals detected at earlier disease stages may have improved treatment outcome. HYPERLINK  \l "_ENREF_15" \o "Squire, 2005 #3"  ADDIN EN.CITE <EndNote><Cite><Author>Squire</Author><Year>2005</Year><RecNum>3</RecNum><DisplayText><style face="superscript">15</style></DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Squire, S. B.</author><author>Belaye, A. K.</author><author>Kashoti, A.</author><author>Salaniponi, F. M.</author><author>Mundy, C. J.</author><author>Theobald, S.</author><author>Kemp, J.</author></authors></contributors><auth-address>Clinical Research Group, Liverpool School of Tropical Medicine, Liverpool, United Kingdom. sbsquire@liv.ac.uk</auth-address><titles><title>&apos;Lost&apos; smear-positive pulmonary tuberculosis cases: where are they and why did we lose them?</title><secondary-title>Int J Tuberc Lung Dis</secondary-title></titles><periodical><full-title>Int J Tuberc Lung Dis</full-title></periodical><pages>25-31</pages><volume>9</volume><number>1</number><edition>2005/01/29</edition><keywords><keyword>Adult</keyword><keyword>Demography</keyword><keyword>Diagnosis, Differential</keyword><keyword>Female</keyword><keyword>Focus Groups</keyword><keyword>Follow-Up Studies</keyword><keyword>Health Status</keyword><keyword>Humans</keyword><keyword>Malawi</keyword><keyword>Male</keyword><keyword>*Patient Dropouts</keyword><keyword>Registries/*statistics &amp; numerical data</keyword><keyword>Risk Factors</keyword><keyword>Social Class</keyword><keyword>Sputum/microbiology</keyword><keyword>Time Factors</keyword><keyword>Tuberculosis, Pulmonary/*diagnosis/*therapy</keyword></keywords><dates><year>2005</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1027-3719 (Print)&#xD;1027-3719 (Linking)</isbn><accession-num>15675546</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=15675546</url></related-urls></urls><language>eng</language></record></Cite></EndNote>15 Second, the new diagnostic will have effects at the health systems level; in particular, there may be initial, or ongoing, investment in equipment, training, and personnel requirements associated with the new tool. Third, new diagnostics may also positively impact the epidemiology of TB in a community. In particular, if the new tool is associated with increased case detection and treatment, it will likely reduce the prevalence of infectious source cases and thus reduce TB transmission. 





Assessing the total effect of a new diagnostic tool requires attention not only to individual benefits, but also health systems-level and population-level impact of interventions. Because field-testing of all possible uses and combinations of interventions is not feasible and the effects will likely differ between settings, we propose a modelling framework to help inform local decision-making. The interrelated nature of the patient-, heath system-, and population-level effects suggests the benefit of developing a linked operational and transmission model that can simulate feedback in the system and expand our ability to compare the total effect of diagnostic strategies. Before presenting our linked model, we briefly describe the general approaches typically used for operational and dynamic epidemiological modelling.

Operational Models 
Operational models have been widely used to plan and assess the performance and efficiency of processes in industrial and commercial settings18-20 and have been increasingly used to help improve the performance in the health sector.21, 22 Some previous applications include models of automotive manufacturing facilities23, 24 and retail operations. HYPERLINK  \l "_ENREF_25" \o "Siebers,  #132"  ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>Siebers</Author><RecNum>132</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>132</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Siebers, PO</author><author>Aickelin, U</author><author>Celia, H</author><author>Clegg, CW</author></authors></contributors><titles><title>Towards the development of a simulator for investigating the impact of people management practices on retail performance</title><secondary-title>Journal of Simulation</secondary-title></titles><periodical><full-title>Journal of Simulation</full-title></periodical><pages>online publication 1 October 2010; doi: 10.1057/jos.2010.20</pages><dates></dates><urls></urls></record></Cite></EndNote>25 While there are many examples of operational modelling of health systems in the developed world, to our knowledge there are few applied to model health systems in low or middle income countries.26, 27

Many operational models use a discrete event simulation approach where the system modelled is first defined in terms of its most important elements including the items or people processed through the facility, resources, activities, rules, and the process flow. The required outputs of the model are defined (e.g. productivity, costs, identification of bottlenecks, capacity, and sensitivity to changes) along with the key input parameters to be investigated. Once the system is defined and appropriate parameter inputs are assigned (e.g. the number of items entering the system, the quantity of resources, and the time for completing particular activities), then simulations can be run to assess the relative effect of different assumptions about the values of input parameters on model output.   

Dynamic Epidemiological Models
Mathematical models that describe the within-host natural history of infection and allow for the simple representation of transmission have offered many insights into the dynamics of infectious diseases in communities and approaches for disease control. HYPERLINK  \l "_ENREF_28" \o "Anderson, 1991 #114"  ADDIN EN.CITE <EndNote><Cite><Author>Anderson</Author><Year>1991</Year><RecNum>114</RecNum><DisplayText><style face="superscript">28</style></DisplayText><record><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Anderson, R.M.</author><author>May, R.M.</author></authors></contributors><titles><title>Infectious Diseases of Humans: Dynamics and Control.</title><secondary-title>Oxford University Press</secondary-title></titles><periodical><full-title>Oxford University Press</full-title></periodical><dates><year>1991</year></dates><urls></urls></record></Cite></EndNote>28 

Many of these models are formulated as differential equation models that specify how a population is divided into mutually exclusive health states (e.g. susceptible to infection, infectious, recovered) and how the flow of individuals between states depends on the current state of the system (e.g. how the incidence of infection depends on the prevalence of disease in the population). Outputs of these models are most naturally shown as trends in the proportion of population in each state over time (e.g. the prevalence of disease), but can also provide insight into more complex considerations of cost-effectiveness associated with interventions. ADDIN EN.CITE 29, 30 While some insight from simple models can be gained through analytical approaches, more complicated models usually require numerical simulation. Once the model equations and input parameters (e.g. rate of recovery from infectiousness, treatment coverage levels, disease associated mortality) are defined, simulation permits the rapid comparison of the relative impact of different modelled interventions. 


A Linked Operational and Dynamic Epidemiological Model for a new TB diagnostic
The operational model component is structured to reflect diagnostic pathways for TB suspects, specimen collection and laboratory procedures, and treatment algorithms for TB patients based on the current WHO guidelines. HYPERLINK  \l "_ENREF_31" \o "World Health Organization, 2009 #40"  ADDIN EN.CITE <EndNote><Cite><Author>World Health Organization</Author><Year>2009</Year><RecNum>40</RecNum><DisplayText><style face="superscript">31</style></DisplayText><record><rec-number>40</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">40</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>World Health Organization,</author></authors></contributors><titles><title>Treatment of tuberculosis: guidelines – 4th ed.</title></titles><dates><year>2009</year></dates><pub-location>WHO/HTM/TB/2009.420</pub-location><urls></urls></record></Cite></EndNote>31 The model structure includes entities (e.g. patients, sputum, samples, and vehicles), activities (e.g. sputum collection, microscopy, and diagnosis), queues (e.g. patient waiting areas and samples waiting to be processed), and resources (e.g. microscopy technicians and clinicians). A simplified diagram of the process for suspects seeking TB diagnosis and then subsequent treatment as appropriate is shown in Figure 2. All activities from TB suspects arriving at the diagnostic centre, through reception, sputum collection, consultation, diagnosis, and treatment are modelled. This includes patients returning home between sputum sample collections and before diagnosis is received. Diagnostic algorithms for new TB suspects and retreatment patients are represented in the model. Sample collection and sputum examination by microscopy are also modelled in detail at the diagnostic centre and in the reference laboratory. At the reference laboratory culture and drug sensitivity testing is performed consistent with current diagnostic and treatment algorithms.27
 
Necessary input data for and output from the operational model are provided in Table 2. We use the WITNESS modelling tool, HYPERLINK  \l "_ENREF_32" \o "Lanner,  #123"  ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>Lanner</Author><RecNum>123</RecNum><DisplayText><style face="superscript">32</style></DisplayText><record><rec-number>123</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">123</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Lanner</author></authors></contributors><titles><title>WITNESS PwE 2.0 Service and Process Performance Edition.</title></titles><number>26 Jan 2011</number><dates></dates><urls><related-urls><url>http://www.lanner.com/en/witness.cfm</url></related-urls></urls></record></Cite></EndNote>32 which is discrete event simulation software, to produce the simulation results. The WITNESS software utilizes a graphical-based approach that allows for a simple visual representation of model processes; these graphical features facilitate communication between model developers and decision makers and allows for rapid development, validation, and simulation. 

The dynamic epidemiological component is based in a differential equation model that captures the most important features of the natural history of TB (Figure 3, top panel) HYPERLINK  \l "_ENREF_33" \o "Blower, 1995 #115"  ADDIN EN.CITE <EndNote><Cite><Author>Blower</Author><Year>1995</Year><RecNum>115</RecNum><DisplayText><style face="superscript">33</style></DisplayText><record><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Blower, S. M.</author><author>McLean, A. R.</author><author>Porco, T. C.</author><author>Small, P. M.</author><author>Hopewell, P. C.</author><author>Sanchez, M. A.</author><author>Moss, A. R.</author></authors></contributors><auth-address>Department of Epidemiology &amp; Biostatistics, University of California San Francisco, San Francisco General Hospital 94143-1347, USA.</auth-address><titles><title>The intrinsic transmission dynamics of tuberculosis epidemics</title><secondary-title>Nat Med</secondary-title></titles><periodical><full-title>Nat Med</full-title></periodical><pages>815-21</pages><volume>1</volume><number>8</number><edition>1995/08/01</edition><keywords><keyword>*Disease Outbreaks</keyword><keyword>Europe/epidemiology</keyword><keyword>Humans</keyword><keyword>*Models, Statistical</keyword><keyword>Nonlinear Dynamics</keyword><keyword>North America/epidemiology</keyword><keyword>Sampling Studies</keyword><keyword>Time Factors</keyword><keyword>Tuberculosis, Pulmonary/*epidemiology/transmission</keyword></keywords><dates><year>1995</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>1078-8956 (Print)&#xD;1078-8956 (Linking)</isbn><accession-num>7585186</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/7585186</url></related-urls></urls><language>eng</language></record></Cite></EndNote>33. As with many TB transmission models, we include states that include individuals who are Susceptible (S), Latently infected (Lf and Ls), Infectious (Isp and Isn), and Recovered (R). Several previous assessments of the potential impact of new diagnostics on transmission dynamics of TB have simply decreased the average infectious period for those with TB by increasing the rate at which individuals recover, but this approach cannot account for how the diagnostic will operate within existing diagnostic pathways. ADDIN EN.CITE 34, 35 To incorporate the health system context where the diagnostic tool will be employed, we further expand the active disease states of the model to include the details of the pathway from disease onset to TB diagnosis and initiation of treatment. Figure 3 (top and bottom panels together) illustrates an expanded transmission model using a diagnostic algorithm for a pulmonary TB suspect that is based on sputum smear microscopy and chest X-ray for smear negative cases. By incorporating the patient pathway and mechanisms of action of diagnostic tools within the health system context, the expanded transmission model provides a platform to systematically understand how the improved test characteristics of new tools can be translated into population impact on transmission and epidemiology of TB. Necessary input data for and output from the transmission model are provided in Table 2. We use Berkeley Madonna (Berkeley Madonna 8.3.18) as our numerical solver for this differential equation model. 

The operational and dynamic epidemiological model components are linked by using selected outputs of one model to serve as the inputs into the other. For example the incidence of TB is an output of the transmission model; this informs the input into the operational model through the number of TB suspects coming for diagnosis in the health system (see Table 2). 

Model scenarios










The Stop TB Partnership's New Diagnostics Working Group has described a pathway from need assessment to delivery for evidence-based policies for TB diagnosis; this includes concept formation, development, evaluation, demonstration, scale-up, and epidemiological impact. HYPERLINK  \l "_ENREF_36" \o "Stop TB Partnership's New Diagnostics Working Group,  #116"  ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>Stop TB Partnership&apos;s New Diagnostics Working Group</Author><RecNum>116</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Stop TB Partnership&apos;s New Diagnostics Working Group, World Health Organization. </author></authors></contributors><titles><title>Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics</title></titles><pages>WHO, 2009</pages><volume>Geneva, Switzerland</volume><dates></dates><urls></urls></record></Cite></EndNote>36 Most existing research on TB diagnostics has taken the form of studies to measure the sensitivity and specificity of new tools, ADDIN EN.CITE 1, 3 systematic reviews of these types of studies, ADDIN EN.CITE 2, 37 and demonstration projects. HYPERLINK  \l "_ENREF_38" \o "Barnard, 2008 #133"  ADDIN EN.CITE <EndNote><Cite><Author>Barnard</Author><Year>2008</Year><RecNum>133</RecNum><DisplayText><style face="superscript">38</style></DisplayText><record><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Barnard, M.</author><author>Albert, H.</author><author>Coetzee, G.</author><author>O&apos;Brien, R.</author><author>Bosman, M. E.</author></authors></contributors><auth-address>Foundation for Innovative New Diagnostics, 71 av Louis-Casai, 1216 Cointrin, Switzerland.</auth-address><titles><title>Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa</title><secondary-title>Am J Respir Crit Care Med</secondary-title></titles><periodical><full-title>Am J Respir Crit Care Med</full-title></periodical><pages>787-92</pages><volume>177</volume><number>7</number><edition>2008/01/19</edition><keywords><keyword>Antitubercular Agents/*pharmacology</keyword><keyword>Genotype</keyword><keyword>Humans</keyword><keyword>Isoniazid/*pharmacology</keyword><keyword>Microbial Sensitivity Tests</keyword><keyword>*Molecular Probe Techniques</keyword><keyword>Mycobacterium tuberculosis/*drug effects/genetics</keyword><keyword>Reagent Kits, Diagnostic</keyword><keyword>Rifampin/*pharmacology</keyword><keyword>Sensitivity and Specificity</keyword><keyword>South Africa</keyword><keyword>Sputum/microbiology</keyword><keyword>Time Factors</keyword><keyword>Tuberculosis, Multidrug-Resistant/*diagnosis</keyword></keywords><dates><year>2008</year><pub-dates><date>Apr 1</date></pub-dates></dates><isbn>1535-4970 (Electronic)&#xD;1073-449X (Linking)</isbn><accession-num>18202343</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/18202343</url></related-urls></urls><electronic-resource-num>200709-1436OC [pii]&#xD;10.1164/rccm.200709-1436OC</electronic-resource-num><language>eng</language></record></Cite></EndNote>38 While accurate and efficient diagnostic tools are essential, technological advances alone will not ensure better TB control. The overall effect of these diagnostic tools depends on whether the tools improve the timeliness of administration of effective treatment. Accordingly, understanding the potential effects of diagnostic tools requires consideration of how these tools may modify access to diagnostic services, the loss of patients during the diagnostic (and treatment) processes, and the burdens on and performance of the health system itself. HYPERLINK  \l "_ENREF_10" \o "Mann, 2010 #113"  ADDIN EN.CITE <EndNote><Cite><Author>Mann</Author><Year>2010</Year><RecNum>113</RecNum><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mann, G.</author><author>Squire, S. B.</author><author>Bissell, K.</author><author>Eliseev, P.</author><author>Du Toit, E.</author><author>Hesseling, A.</author><author>Nicol, M.</author><author>Detjen, A.</author><author>Kritski, A.</author></authors></contributors><auth-address>Liverpool School of Tropical Medicine, Liverpool, UK.</auth-address><titles><title>Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools</title><secondary-title>Int J Tuberc Lung Dis</secondary-title></titles><periodical><full-title>Int J Tuberc Lung Dis</full-title></periodical><pages>1518-24</pages><volume>14</volume><number>12</number><edition>2010/12/15</edition><dates><year>2010</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1815-7920 (Electronic)&#xD;1027-3719 (Linking)</isbn><accession-num>21144235</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/21144235</url></related-urls></urls><language>eng</language></record></Cite></EndNote>10 

Projecting the overall effects of scaled-up use of a diagnostic tool with improved test characteristics is not easy. First, the design of field studies to evaluate the epidemiological impacts of a new tool presents a major challenge: the impact on transmission cannot be easily observed because of the slow intrinsic dynamics of TB.   Incomplete case notification in most areas further complicates the interpretation of trend data for TB incidence. Second, understanding how the adoption of a new diagnostic tool affects overall flow of patients and specimens (and resultant burdens on personnel and equipment) is not easy to predict and requires a detailed understanding of diagnostic pathways and health systems infrastructure. In this paper, we discuss the role of operational and dynamic epidemiological models for comparing the potential overall effects of different diagnostic tools and strategies.

We have provided a rationale for linking operational and dynamic epidemiological models and the simple results included here show how the test characteristics of diagnostic tools (e.g. sensitivity and number of specimens required for diagnosis) have an effect on important epidemiological parameters (e.g. initial defaults during diagnosis and thus the average duration of infectiousness). Similarly, changing epidemiological parameters (e.g. TB incidence) affect the demand on health systems (e.g. TB suspects requiring diagnostic services). However, we also believe that operational models and dynamic epidemiological models can also be of tremendous use when used independently of one another. For example, analysis of the operational model developed here shows the non-trivial impact of a new, more sensitive diagnostic tool on the number of patients requiring treatment services (see Table 4). This type of effect is important to anticipate in advance of adopting a new diagnostic strategy. Similarly, the dynamic epidemiological model can itself provide important insight into how improved diagnostic performances (e.g., test sensitivity) translate into reduced TB incidence and how external factors (e.g., patient delay in seeking medical attention and lost to follow-up along the patient pathway) could undermine their effects. Further research is required to identify the circumstances in which linked models result in substantially different inference than models used in parallel.

This modelling framework identifies several types of input that are important to project the impact of diagnostic tools. In many settings, detailed knowledge of flows (of patients, specimens, and information) and related bottlenecks in the health system may not be available. Models that include operational components demonstrate why these logistical issues are important for predicting the effectiveness of diagnostic tools and sensitivity and uncertainty analysis can be used to identify which unknown operational components are most important to measure. 

The goal of this model development activity is to demonstrate the feasibility of the linked modelling approach. An essential consideration that we have not included in the model results presented here is the costs and comparative cost-effectiveness of different diagnostic strategies.  As noted above, modelling provides an opportunity for attaching health system and patient costs to the different elements of a diagnostic process and weighting them by the probability of each element taking place, including accounting for the impact of bottlenecks and economies of scale.  The operational model can be run for multiple years enabling longer term cost projections to be considered.  

Health economic modelling has typically used static decision-models with a focus on health system costs. ADDIN EN.CITE 39 Such models do not allow for assessing the longer-term impacts on epidemiology.  In our linked model, the long term impact of a new diagnostic on TB epidemiology can be projected from the dynamic epidemiological component of the model.  Linked modelling therefore allows for a broader range of outcomes to be assessed against cost, such as infections or deaths averted over longer time frames. Models can also be structured to allow for outcomes and costs faced by groups of patients disaggregated by factors such as HIV status, poverty and gender.  Thus, the likely effects of new diagnostic strategies on health equity can also be assessed.   

We have also not included drug-resistant TB in the transmission component of the current model, but plan to expand this work to consider diagnostics that detect drug-resistant TB. Models that include drug resistance and costs will be used in future work that addresses more realistic decisions faced by country-level decision makers. For example, there are many current questions related to the potential impact of GeneXpert3 as a replacement for (or in addition to) microscopy as specified in the WHO recommended algorithms that would be amenable to study with these models.40, 41 
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Table 1: Potential effects of a new diagnostic tool

EFFECT LEVEL	METRICS
Patient	Diagnosis outcomes and time to diagnosisTreatment outcomes and time to cure/failNumber of visits to health system requiredCost per health facility visit
Health System	Staff requirements by skill type and shift patternEquipment requirementsHealth system investment and ongoing costsTreatment requirements and costsCapacity of the health system and bottlenecks






Table 2 – List of inputs into and outputs from the operational model and transmission model. The linkage between the two models results from using model outputs from one model as inputs for the other.


Table 3: Test Scenarios
TEST SCENARIOS	Number of sputum samples	Lab Time needed per sample	Sensitivity of Diagnostic among new pulmonary  TB cases 



















Figure 2: Simplified diagram of TB diagnostic and treatment process

The figure shows the flow for patients and samples through a single diagnostic centre with samples being transported to a central reference laboratory for drug sensitivity if that is necessary. TB suspects are referred to the diagnostic centre for testing where they provide a sputum sample which is examined using microscopy. In the base case a second sample is required so suspects return home, returning the next day to provide a second sample. Some suspects will receive diagnosis the same day, others may have to return home and return a subsequent day to receive diagnosis. If diagnosed with TB they will receive treatment and return home – see icon in top right. TB patients are required to return to the diagnostic centre every 2 weeks to receive subsequent medication. Therapeutic monitoring requires TB patients to return to the diagnostic centre for further sputum examination at three points during therapy: at the end of the intensive phase (month 2 for new patients, month 3 for retreatment patients), at month 5 for all patients and at treatment completion (month 6 for new patients and month 8 for retreatment patients).  If smears are positive during these follow up assessment, further specimens are required for microscopy, culture and DST at the reference laboratory in accordance with current WHO guidelines. HYPERLINK  \l "_ENREF_31" \o "World Health Organization, 2009 #40"  ADDIN EN.CITE <EndNote><Cite><Author>World Health Organization</Author><Year>2009</Year><RecNum>40</RecNum><DisplayText><style face="superscript">31</style></DisplayText><record><rec-number>40</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">40</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>World Health Organization,</author></authors></contributors><titles><title>Treatment of tuberculosis: guidelines – 4th ed.</title></titles><dates><year>2009</year></dates><pub-location>WHO/HTM/TB/2009.420</pub-location><urls></urls></record></Cite></EndNote>31 Every time a patient returns home there is a probability that they will not return to the diagnostic centre and therefore will be lost to follow-up or treatment. 

Figure 3: Graphical representation of the compartmental transmission dynamic model. 

The upper part of the figure shows a structure that is similar to many TB transmission models: The susceptible population (S), once exposed to infectious cases, may be infected and enter the latent infection states (Lf for early latent stage and Ls for late latent stage). Latently infected people can progress (from Lf) or reactivate (Ls) to the active disease state. Patients with active disease have either smear-positive pulmonary (Isp) or smear-negative pulmonary (Isn) disease (those with extrapulmonary TB do not contribute to the transmission dynamics of TB and therefore are not accounted for in this model). Those with TB may recover from disease through case detection and treatment (R), self-cure and return to the latent infection state, or die from TB. 









Page 25 of 25



